Bronchoscopic lung volume reduction method

Abstract

A method of minimally invasively reducing a volume of a hyper-inflated target section of diseased lung comprising the steps of introducing a bronchoscope into a patient's airway to a position adjacent the target section and equilibrating air within the target section with atmospheric air to at least partially deflate the target lung section; injecting an inflammation-causing substance into the target section to precipitate adhesion of the walls within the target lung section, preventing substantial re-inflation of the target section by occluding an airway upstream of the target section for a period of time, and removing the airway occlusion after the target section has substantially permanently been reduced in volume. The injected substance can be autologous blood or a constituent thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The present application is a continuation of U.S. application Ser. No. 10 / 409,785, filed Apr. 8, 2003, the entire contents of which is incorporated herein by reference.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The invention relates in general to the field of pulmonary disease treatments, and specifically to a bronchoscopic method of performing lung volume reduction surgery using an obstruction or one-way valve. [0004] 2. Description of the Related Art [0005] The lungs deliver oxygen to the body by directing air through numerous air passageways that lead from the trachea to respiratory bronchiole to small sacs called alveoli. These alveoli are generally grouped together in a tightly packed configuration called an alveolar sac, and surround both alveolar ducts and respiratory bronchiole throughout the lung. The alveoli are small, polyhedral recesses composed of a fibrillated connective tissue and surrounded by a ...

AI Technical Summary

Benefits of technology

[0012] In one application of the present method, the distal end of a bronchoscope is used to guide the catheter to a diseased lung section, where an inflammation-causing substance is injected into the diseased lung section. In one variation, the present method comprises using the distal end of a bronchoscope to guide a multilumen catheter to a position adjacent the target region, inserting a puncturing tip through a section of diseased lung tissue and into the target region, and equilibrating the target region with atmospheric air. The target region air is equilibrated through a lumen extending from a distal opening of the lumen to the atmosphere. With the target region at atmospheric pressure, one or more occlusion devices may then be deployed in airways leading into the target region, thereby isolating the target region from inspiratory air flow. In one application, the obstruction is a one-way valve, such as those described in the '951 and '100 Alferness patents, or those described in pending U.S. patent application Ser. Nos. 09 / 951,105 to Alferness et al. filed on Sep. 11, 2001, Ser. No. 10 / 104,487 to Alferness et al. filed on Mar. 30, 2002, and Ser. No. 10 / 124,790 to DeVore filed on Apr. 16, 2002. The entire disclosures of the above patents and applications are incorporated herein by reference and made part of the present disclosure. The advantage of an obstruction device is reduced risk of reinflation during the adhering process, resulting in more effective lung volume reduction. Another advantage, among others, is precluding migration of the injected substance to non-targeted regions of the lung.

Problems solved by technology

Patients with chronic obstructive pulmonary disease or emphysema have reduced lung function and efficiency, typically due to the breakdown of lung tissue.

Lung tissue and alveoli are destroyed, reducing the supportive structure of the airways.

This reduction in strength of the airway walls allows the walls to become “floppy,” thereby losing their ability to remain open during exhalation.

In this diseased state, the patient suffers from the inability to get the air out of their lungs due to the loss of elasticity of the lungs as well as the collapse of the airways during exhalation.

Within the confines of the chest cavity, this hyper-inflation restricts the in-flow of fresh air and the proper function of healthier tissue, resulting in significant breathlessness.

With, severe emphysema, when patients take in as much air as their chest cavity can accommodate, they still have insufficient gas exchange because their chest is full of non-functional air filling large cavities in the lungs.

A wide variety of drugs are available for treating the symptoms of chronic obstructive pulmonary disease, but none are curative.

A large number of patients are not responsive to these medications.

This surgery has substantial risks of serious post-operative complications, such as pneumonia, and requires an extended convalescence.

Images